Scientific Resources
Oncology
- Simoni et al., Clinical & Translational Immunology 2020, Partial absence of PD‐1 expression by tumor‐infiltrating EBV‐specific CD8+ T cells in EBV‐driven lymphoepithelioma‐like carcinoma
- Chiu et al, Gastroenterology 2020, Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
- Fehlings et al., J Immunother Cancer 2019, Neoantigen-specific T cells in atezolizumab-treated patients High-dimensional Characterization of the Systemic Immune Landscape Informs on Synergism between Radiotherapy and Immune Checkpoint Blockade
- Simoni et al., Nature 2018, Characterization of antigen-specific T cells in human tumors
- Fehlings M, et al., Nature Communications 2017, Measuring checkpoint inhibitors biological activity in a tumor model
General Immunology
- Simoni Y, et al., Immunity 2017, Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency
- Wong MT, et al., Immunity 2016, Cytokine & trafficking patterns of T cells across human tissues
- Wong MT, et al., Cell Reports 2015, T cell diversity in human blood and tonsilsT cell diversity in human blood and tonsils
- Becher B, et al., Nat Immunol. 2014, Characterization of the murine myeloid system
Bioinformatics / Data Science
Infectious Disease
Whitepapers
Read AllTargetScape® – Identifying and Profiling the Cellular Immune Response
To develop immunotherapies for cancer, infectious diseases, autoimmune diseases and other disorders, a need exists for high-dimensional profiling to identify and better understand the role of antigen-specific T cells, the key effectors in many diseases. ImmunoScape’s TargetScape™ can screen and identify antigen-specific CD8 T cells by their recognition of several hundred candidate antigens simultaneously, as well as deeply characterizing their cellular phenotype.
Read our white paper to find out how TargetScape™ can help lead to lower candidate attrition rates during clinical development, mitigate clinical trial failure risk, support overall drug development strategies and replenish your drug pipeline with new targets and improved drug candidates.
Webinars
Read AllAn introduction to ImmunoScape’s approach to identifying and profiling the immune response
High-dimensional immunoprofiling can rationally inform how immunotherapy treatments and vaccines affect and modulate the immune response over time by identifying and quantifying large numbers of different immune cell subsets within blood or tissue samples. To learn more, sign up to receive notifications about ImmunoScape’s new high-dimensional analysis webinar series.
Presented by Michael Fehlings, Ph.D., co-founder and Director, Scientific Affairs, ImmunoScape, the first webinar discussed high-dimensional immunoprofiling citing results from several peer-reviewed publications.